inSeption Group

Modernizing the Trial Master File (TMF) involves much more than a technological upgrade. It consists of streamlining processes and staffing to ensure compliance, efficiency and data integrity, which are critical to meet today’s clinical trial management needs.

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 (R3), 06 January 2025, Guideline for Good Clinical Practice (GCP) emphasizes the importance of a high-quality TMF. Essential records “permit and contribute to the evaluation of the conduct of a trial about the compliance of the investigator and sponsor with Good Clinical Practice (GCP) and applicable regulatory requirements and the reliability of the results produced.”

In addition to ICH E6 (R3), the European Medicines Agency (EMA) GCP Inspectors Working Group “Guideline on the content, management and archiving of the clinical trial master file (paper and/or electronic)” – 06 December 2018 also described that a modern TMF is more than an archival repository. The TMF is a centralized, cloud-based ecosystem that includes all systems containing TMF records. Examples of these systems are Clinical Trial Management System (CTMS), Electronic Data Capture (EDC), Interactive Response Technology (IRT) and Contracts Databases.

Per the ICH E6 (R3) and the EMA Guideline, TMF repositories should be validated, accessible to those needing access to records in the system, accessible to auditors and inspectors, able to be restricted to only records required for an audit or inspection, ability to be “locked” at the end of the study and able to maintain digitally preserved and readable records for 25 years.

The GCP and EMA guidelines mandate that the TMF must enable the reconstruction of the clinical trial. TMF records must meet ALCOA++ principles (attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available and traceable). A contemporaneous (timely filing of records) TMF demonstrates compliance with the regulations and allows the TMF to be used as a study management tool. The guidelines also emphasize proactive QC measures and real-time TMF oversight to ensure TMF health.

Transitioning to a digital TMF is a strategic initiative demanding operational, cultural, and technological shifts with long-term benefits that far outweigh the challenges.

The EMAs 2023 Guideline on computerised systems and electronic data in clinical trials emphasized that TMF systems must support traceability, system interoperability and long-term archiving in alignment with digital health regulations.

A “modern” TMF is much more than a repository. It will have metadata-driven classification for intelligent filing and retrieval using an industry standard filing structure such as the Clinical Data Interchange Standards Consortium TMF reference model; version control with audit trails; automated workflows for filing, review and signatures; reports to monitor completeness, timeliness and quality metrics; and role-based access control.

Regulatory authorities—including the U.S. Food and Drug Administration, EMA and Medicines & Healthcare products Regulatory Agency—expect the TMF to be organized, accessible and inspection-ready at all times.

Common inspection findings include:

• Incomplete or inconsistent TMF documentation

• Delayed document filing

• Poorly defined record ownership and accountability

• Inadequate oversight of TMFs managed by Service Providers

Modern eTMFs address these challenges by enabling real-time oversight and creating transparency across the TMF record lifecycle.

Modernizing the TMF is not just a technical upgrade. It’s a strategic initiative to align with GCP, improve trial execution and ensure inspection readiness. While the path to a digital TMF involves operational, cultural and technological shifts, the long-term benefits far outweigh the growing pains.